Supply ‘constrained’ but improving

Substitution instrument extended for abatacept, while others end The Serious Scarcity Substitution Instrument (SSSI) for abatacept (Orencia), originally set to expire on 30 April, has been extended until 30 June. It was issued by the TGA in February due to shortages caused by “manufacturing delays” for both Orencia subcutaneous formulations—the syringe and the autoinjector (ClickJect).